“…In some cases, this cost can be offset by reducing immunosuppressive therapy, which directly influences outcomes such as hospitalization, quality of life and, sometimes, mortality related to immunosuppressive therapy. 16 However, clinical follow-up studies and economic studies of ECP therapy are still scarce. Thus, this study aims to describe the clinical evolution of patients undergoing ECP as a second-line therapy for cGVHD and to perform an economic analysis of the treatment process.…”